You are here

FDA approval for ixekizumab for psoriasis

Primary tabs

FDA approves ixekizumab for psoriasis. There is a hope that will compete against a new wave of rival therapies for psoriasis.

By 2020, analysts expect IL-17A anti-inflammatory drug to carve out a market worth more than a billion dollars a year. Few weeks ago, the European Medicines Agency signalled its approval for the therapy, giving way to another big market later this year.

Inflammation is triggered when ixekizumab binds to the protein interleukin (IL)-17A. Lilly aimed for a top role in the market by inculcating head-to-head late-stage studies against market leaders, plus Etanercept.

Many people living with plaque psoriasis are looking for another treatment option for this disease. With this FDA approval, this drug provides significant improvement of psoriasis plaques." As per Dr. Julie Beitz, director of the Office of Drug Evaluation III in FDA's Center for Drug Evaluation and Research, “Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition."

AUDIO-VISUAL ROOM

Event Calendar

FUN ZONE

Medznat, an initiative of Dr. Reddy’s Laboratories Ltd., is a resource for practicing doctors to enable their continuous learning. It provides unbiased and relevant medical information, apart from several other useful resources to aid their daily practice.

Medznat brings together premium content from leading publishers globally, to deliver comprehensive and up-to-date medical information.

Content Source

Medznat presents current medical information from the world's leading sources - the largest databases PubMed and DOAJ. Translation of articles made by ABBYY-LS

The scientific editors of the Medznat website make sure that our publications are accurate, simple and useful to the readers. We are always glad for your questions or suggestions!

Dr. Reddy’s Laboratories Ltd. dose not endores and its not responsible for the accuracy of the content, or for practices or standards of Dr. Reddy’s Laboratories Ltd sources. Please read our Terms of Use for more information